Seeking Alpha
18 Nov 2026, 14:42 UTC · 4h ago
Convatec Group PLC (CNVVY) 10 Months Period Ending/ Trading Statement Call Transcript
Impact · against what's priced in
Convatec is upgrading its FY2026 revenue growth outlook and confirming double-digit EPS growth, driven by acceleration in Infusion and Continence Care. The organic revenue growth of 6.6% (ex-InnovaMatrix) suggests the core business is outperforming recent acquisitions.
- CNVVY+0.60
No priced-in read yet
- In context
The company is upgrading its full-year revenue growth range and reiterating double-digit EPS growth, supported by 6.6% organic growth in the legacy business for the first 10 months.
Read from the article alone

Search tags




